Markets have fallen almost 10 per cent from their recent highs, although they recovered a little on Friday. Here are a few stocks that look attractive from the medium to long term perspective.
Andhra Bank is confident of improving its asset quality as issues faced by power and infrastructure sector, which constitutes ~10 & 16% of loan book and ~55% of its restructured assets, are being sorted out and many companies are reviving operations as evident from low slippages in restructured accounts and reduction in slippage for four consecutive quarters. We maintain our BUY rating on the stock with target price of INR 135, based on 1x FY17E ABV, " the firm has stated.
Emkay is bullish on Axis Bank and has recommended a buy rating on the stock with a target price of Rs 605 on the stock.
"We maintain our Accumulate rating, as the bank's retail-asset focus, better deposit franchise and stable asset quality are likely to sustain a 1.8% RoA over FY15-17. We expect the stock to trade at higher-than-past valuations led by likely better than-past asset quality. At our Mar'17 target, it would trade at PABV of 2.8x FY16e and 2.4x FY17e. Our target is based on the two-stage DDM (CoE: 16%; beta: 1.2; Rf: 7.5%)," the firm has stated
Sunidhi Securities is bullish on the stock of Claris Lifesciences. The firm has recommended buying the stock with a target price of Rs 412.
Founded in 1999, CLSL is a multi-business enterprise and the Holding Company of Claris Injectables, a wholly-owned subsidiary dealing in Specialty Injectables business, collectively "Claris"; and „Claris Otsuka‟, a Joint Venture with Japanese Otsuka Pharmaceutical Factory, Inc. & Mitsui & Co. Ltd. for Infusion business in India & emerging markets. Claris has identified itself as a company specialising in sterile injectables technology. Its array of therapies includes anesthesia, blood products, anti-infectives, and plasma volume expanders. The plant is located at Vasna, Ahmedabad in Gujarat.
At the CMP of Rs 260, CLSL share is trading at a P/E of 9.2x on FY16E and 7.6x on FY17E. We recommend BUY with a target price of Rs 412 at a P/E of 12.0x on FY17E.," says the Sunidhi report.